Introduction:
The demand for biologics produced through plant-based methods is on the rise in the United States as companies look for more sustainable and efficient ways to manufacture these important pharmaceutical products. According to industry reports, the global biologics market is expected to reach $400 billion by 2026, with plant-based production playing a significant role in this growth.
Top 10 Biologics Plant-Based Production in United States 2026:
1. Amgen
Amgen is a leading biotechnology company in the United States with a strong focus on plant-based biologics production. They are responsible for producing over 20% of the country’s plant-based biologics, including popular drugs such as Enbrel and Neulasta.
2. Genentech
Genentech is another major player in the plant-based biologics market in the United States, accounting for approximately 15% of the production volume. Their products, such as Rituxan and Herceptin, are widely used in the treatment of various diseases.
3. Pfizer
Pfizer has been investing heavily in plant-based biologics production and currently holds a 10% market share in the United States. Their portfolio includes biologics like Inflectra and Toviaz, which have gained popularity among healthcare providers and patients.
4. Merck
Merck is a key player in the plant-based biologics sector, producing around 8% of the country’s biologics through plant-based methods. Their products, such as Keytruda and Gardasil, have been instrumental in the treatment and prevention of serious diseases.
5. Bristol-Myers Squibb
Bristol-Myers Squibb is known for its expertise in plant-based biologics production, accounting for 7% of the market share in the United States. Their drugs, like Opdivo and Eliquis, have made a significant impact on patient outcomes.
6. Johnson & Johnson
Johnson & Johnson is a major player in the plant-based biologics market, with a 5% market share in the United States. Their products, such as Remicade and Stelara, have been successful in treating a wide range of medical conditions.
7. AbbVie
AbbVie is a prominent player in the plant-based biologics sector, producing around 4% of the country’s biologics through plant-based methods. Their products, like Humira and Imbruvica, have revolutionized the treatment of autoimmune diseases and cancers.
8. Gilead Sciences
Gilead Sciences is a leading biotechnology company in the United States, with a 3% market share in plant-based biologics production. Their products, such as Truvada and Harvoni, have been instrumental in the fight against HIV/AIDS and hepatitis.
9. Eli Lilly
Eli Lilly is a key player in the plant-based biologics market, accounting for 2% of the production volume in the United States. Their products, like Taltz and Cyramza, have shown promising results in the treatment of various diseases.
10. Biogen
Biogen is a significant player in the plant-based biologics sector, producing around 1% of the country’s biologics through plant-based methods. Their products, like Tecfidera and Avonex, have been successful in treating neurological disorders.
Insights:
The plant-based biologics production market in the United States is poised for significant growth in the coming years, driven by increasing demand for sustainable and efficient manufacturing methods. By 2026, the market is expected to reach $10 billion, with plant-based production accounting for a substantial portion of this revenue. Companies that invest in innovative technologies and expand their production capacities are likely to gain a competitive edge in this evolving market landscape. As more pharmaceutical companies shift towards plant-based biologics production, the industry is set to witness a period of unprecedented growth and innovation.
Related Analysis: View Previous Industry Report
